NH TherAguix and CARBOGEN AMCIS announced the release of a new batch of AGuIX Drug Product for clinical trials. CARBOGEN AMCIS SAS just released the fifth batch of AGuIX Drug Product since inception of the company. The release of this 3.7 kg batch added to previous available batches will secure the supply for hospitals and cancer centers that are involved in the clinical trials managed by the company. At present, 4 Phase1b/2 studies are recruiting (brain metastasis, cervix cancer, pancreatic cancer and lung cancer) and 3 are foreseen to start on other indications since already authorized by health authorities. AGuIX combines three essential assets to fight tumors without changing the patient care. It has the potential to target, image and treat cancer after intravenous injection. Its pharmacological potential is related to its innovative design that combines both a metal containing hybrid composition and a nanoscale structure. The manufacturing of the fifth clinical batch of AGuIX Drug Product was performed at CARBOGEN AMCIS French site in Riom.